| Identification | Back Directory | [Name]
Pyrrophenone | [CAS]
341973-06-6 | [Synonyms]
Pyrrophenone
N-[[(2S,4R)-1-[2-(2,4-difluorobenzoyl)benzoyl]-4-tritylsulfanylpyrrolidin-2-yl]methyl]-4-[(E)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]benzamide
Benzamide, N-[[(2S,4R)-1-[2-(2,4-difluorobenzoyl)benzoyl]-4-[(triphenylmethyl)thio]-2-pyrrolidinyl]methyl]-4-[(Z)-(2,4-dioxo-5-thiazolidinylidene)methyl]- | [Molecular Formula]
C49H37F2N3O5S2 | [MDL Number]
MFCD18384946 | [MOL File]
341973-06-6.mol | [Molecular Weight]
849.962 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 12.5 mg/ml; DMSO: 15 mg/ml; DMSO:PBS (pH 7.2) (1:10): 0.1 mg/ml | [form ]
A crystalline solid | [color ]
White to off-white |
| Hazard Information | Back Directory | [Description]
The group IVA phospholipase A2 (PLA2), known as calcium-dependent cytosolic PLA2 (cPLA2), selectively releases arachidonic acid (AA) from membrane phospholipids, playing a central role in initiating the synthesis of prostaglandins (PGs) and leukotrienes (LTs). Pyrrophenone inhibits cPLA2α with an IC50 of 4.2 nM in enzyme assays and potently blocks the release of AA and the production of PGE2 and LTC4 in cells (IC50 = 24, 25, and 14 nM, respectively). Its action is reversible and selective, as pyrrophenone inhibits the secretory type IB and IIA PLA2s with more than a hundred-fold less potency. Pyrrophenone has also been shown to inhibit calcium ionophore (A23187)-stimulated AA release from monocytic cells, interleukin-1-induced PGE2 synthesis in mesangial cells, and the production of PGE2, LTs, and platelet-activating factor by human neutrophils, always with maximal inhibition at concentrations below 1 μM. | [Uses]
Pyrrophenone is a potent and specific cytosolic phospholipase A2α (cPLA2α) inhibitor with an IC50 value of 4.2 nM[1]. | [in vivo]
Pyrrophenone (administered i.p. at 20 mg/kg 30 min before LPS injection.) suppresses bronchoalveolar lavage (BAL) levels of leukotriene B4 (LTB4) and platelet activating factor (PAF)[3]. | Animal Model: | Specific pathogen-free female BALB/c mice[3] | | Dosage: | 20 mg/kg
| | Administration: | Administered i.p. 30 min before LPS injection | | Result: | Suppressed the recruitment of neutrophils and eosinophils, but not macrophages. |
| [IC 50]
cPLA2α: 4.2 nM (IC50) | [References]
[1] K Seno, et al. Pyrrolidine inhibitors of human cytosolic phospholipase A2. Part 2: synthesis of potent and crystallized 4-triphenylmethylthio derivative 'pyrrophenone'. Bioorg Med Chem Lett. 2001 Feb 26;11(4):587-90. DOI:10.1016/s0960-894x(01)00003-8
[2] Stefania Mariggiò, et al. Cytosolic phospholipase A2 alpha regulates cell growth in RET/PTC-transformed thyroid cells. Cancer Res. 2007 Dec 15;67(24):11769-78. DOI:10.1158/0008-5472.CAN-07-1997
[3] C-H Lee, et al. Mechanism of glutamine inhibition of cytosolic phospholipase a2 (cPLA2 ): Evidence of physical interaction between glutamine-Induced mitogen-activated protein kinase phosphatase-1 and cPLA2. Clin Exp Immunol. 2015 Jun;180(3):571-80. DOI:10.1111/cei.12585 |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|